Every 10-Q that CERO TERAPEUTICS HLDG INC (CERO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CERO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CERO filings page.
CERo Therapeutics Holdings, Inc. is an early-stage immunotherapy company developing engineered T cell therapies, including lead candidate CER-1236 in a Phase 1/1b trial for AML, with additional IND clearance for NSCLC and ovarian cancer. The business remains pre-revenue.
For the six months ended June 30, 2026, CERo reported a net loss of $6.9 million, improved from $10.5 million a year earlier, as R&D and G&A expenses declined modestly. However, large deemed dividends on preferred stock brought the net loss attributable to common shareholders to $35.3 million. Operating cash outflows were $5.1 million, funded mainly by $3.7 million of new convertible notes and $0.7 million from an equity line of credit.
Liquidity is strained: cash and equivalents were $0.94 million, total assets $1.9 million, against $32.4 million of liabilities and a stockholders’ deficit of $30.5 million. Management discloses a working capital deficit of about $30.9 million and states that these conditions raise substantial doubt about the company’s ability to continue as a going concern. Trading in the common stock moved from Nasdaq to the OTCQB market after an October 2025 delisting.
CERo Therapeutics Holdings, Inc. reports Q1 2026 results showing continued operating losses and tight liquidity. The company posted a net loss of about $5.9 million for the quarter on operating expenses of roughly $4.8 million, primarily for research and development and general and administrative costs.
Cash, restricted cash and cash equivalents were only $857,489 as of March 31, 2026, while net cash used in operating activities was about $2.8 million. Total assets of roughly $2.2 million compare with total liabilities of about $11.5 million, resulting in stockholders’ deficit of approximately $9.3 million and a working capital deficit of about $9.8 million.
Management explicitly states that these conditions, together with an accumulated deficit of about $96.7 million and lack of revenue, raise substantial doubt about CERo’s ability to continue as a going concern within one year. To help fund operations, CERo raised about $2.0 million net during the quarter through equity line drawdowns and new 10% convertible notes, which also created significant derivative liabilities. The company remains an early-stage immunotherapy developer, with its lead T cell therapy CER-1236 in Phase 1/1b trials for acute myelogenous leukemia and prior FDA clearance of an IND for additional indications. CERo’s shares now trade on the OTCQB following a 2025 Nasdaq delisting.
CERo Therapeutics Holdings (CERO) reported a wider net loss and mounting cash pressure for the quarter ended September 30, 2025. The company posted a quarterly net loss attributable to common shareholders of $11.5 million and a nine‑month net loss of $47.1 million, driven by research and development expenses of $8.0 million and general and administrative costs of $6.0 million for the year to date.
Cash, restricted cash and cash equivalents were $2.0 million at September 30, 2025, against total liabilities of $8.5 million and an accumulated deficit of $86.3 million, leading management to state there is “substantial doubt” about the company’s ability to continue as a going concern.
To fund operations, CERo raised capital through common stock, pre‑funded warrants and Series D preferred stock, generating several million dollars of net proceeds in 2025, but it continues to rely on external financing. Operationally, the FDA cleared its IND for lead candidate CER‑1236 in AML, and by September 2025 three patients had been dosed in a Phase 1/1b trial. A second IND for NSCLC and ovarian cancer was accepted in March 2025. However, Nasdaq has decided to delist the company’s shares, which now trade on the OTC Pink Sheets.
CERo Therapeutics Holdings, Inc. reported interim results showing limited cash runway, ongoing operating losses and material financing activity. The company had approximately $3.23 million in cash and cash equivalents at June 30, 2025 and an accumulated deficit of approximately $81.4 million. For the six months ended June 30, 2025 the Company recorded a net loss of $5.42 million, and a year-to-date net loss of $10.52 million for 2024 comparisons presented. During the period the Company raised proceeds of approximately $4.2 million from a February 2025 securities offering, $2.9 million from warrant exercises, subscriptions and ELOC fundings, and $2.2 million from sales of Series D preferred stock. The filing discloses substantial doubt about the Company’s ability to continue as a going concern without additional financing. The Company effected reverse stock splits and recorded significant preferred-to-common conversions and related deemed dividends and stock-based inducement expenses that materially affected reported equity and net loss.